A van der Hout1,2, K Holtmaat1,2,3, F Jansen2,3, B I Lissenberg-Witte4, C F van Uden-Kraan1,2, G A P Nieuwenhuijzen5, J A Hardillo6, R J Baatenburg de Jong6, N L Tiren-Verbeet7, D W Sommeijer8,9, K de Heer8,10, C G Schaar11, R J E Sedee12, K Bosscha13, M W M van den Brekel14, J F Petersen14, M Westerman15, J Honings16, R P Takes16, I Houtenbos17, W T van den Broek18, R de Bree19, P Jansen20, S E J Eerenstein2,3, C R Leemans3, J M Zijlstra2,21, P Cuijpers1, L V van de Poll-Franse22,23,24, I M Verdonck-de Leeuw1,2,3. 1. Department of Clinical, Neuro- and Developmental Psychology, Amsterdam Public Health research institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. 2. Cancer Center Amsterdam (CCA), Amsterdam UMC, Amsterdam, The Netherlands. 3. Department of Otolaryngology - Head and Neck Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. 4. Department of Epidemiology and Data Science, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. 5. Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands. 6. Department of Otolaryngology and Head and Neck Surgery, Erasmus MC Cancer Centre, Erasmus Medical Center, Rotterdam, The Netherlands. 7. Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands. 8. Department of Internal Medicine, Flevoziekenhuis, The Netherlands. 9. Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. 10. Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. 11. Department of Internal Medicine, Gelre Ziekenhuis, Apeldoorn, The Netherlands. 12. Department of Otolaryngology, Head and Neck Surgery, Haaglanden MC, The Hague, The Netherlands. 13. Department of Surgery, Jeroen Bosch Ziekenhuis, Den Bosch, The Netherlands. 14. Department of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands. 15. Department of Hematology, Northwest Clinics, Alkmaar, The Netherlands. 16. Department of Otorhinolaryngology - Head and Neck Surgery, Radboud University Medical Center, Nijmegen, The Netherlands. 17. Department of Hematology, Spaarne Gasthuis, Hoofddorp, The Netherlands. 18. Department of Surgery, St. Anna Hospital, Geldrop, The Netherlands. 19. Department of Head and Neck Surgical Oncology, Utrecht University Medical Center, Utrecht, The Netherlands. 20. Department of Surgery, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands. 21. Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. 22. CoRPS - Center of Research on Psychological and Somatic disorders, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, The Netherlands. 23. Department of Research, Netherlands Comprehensive Cancer Organisation, Eindhoven, The Netherlands. 24. Division of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Oncokompas is a web-based self-management application that supports cancer survivors to monitor their health-related quality of life (HRQOL) and symptoms, and to obtain personalised feedback and tailored options for supportive care. In a large randomised controlled trial among survivors of head and neck cancer, colorectal cancer, and breast cancer and (non-)Hodgkin lymphoma, Oncokompas proved to improve HRQOL, and to reduce several tumour-specific symptoms. Effect sizes were however small, and no effect was observed on the primary outcome patient activation. Therefore, this study aims to explore which subgroups of cancer survivors may especially benefit from Oncokompas. MATERIALS AND METHODS: Cancer survivors (n = 625) were randomly assigned to the intervention group (access to Oncokompas, n = 320) or control group (6 months waiting list, n = 305). Outcome measures were HRQOL, tumour-specific symptoms, and patient activation. Potential moderators included socio-demographic (sex, age, marital status, education, employment), clinical (tumour type, stage, time since diagnosis, treatment modality, comorbidities), and personal factors (self-efficacy, personal control, health literacy, Internet use), and patient activation, mental adjustment to cancer, HRQOL, symptoms, and need for supportive care, measured at baseline. Linear mixed models were performed to investigate potential moderators. RESULTS: The intervention effect on HRQOL was the largest among cancer survivors with low to moderate self-efficacy, and among those with high personal control and those with high health literacy scores. Cancer survivors with higher baseline symptom scores benefitted more on head and neck (pain in the mouth, social eating, swallowing, coughing, trismus), and colorectal cancer (weight) specific symptoms. DISCUSSION: Oncokompas seems most effective in reducing symptoms in head and neck cancer and colorectal cancer survivors who report a higher burden of tumour-specific symptoms. Oncokompas seems most effective in improving HRQOL in cancer survivors with lower self-efficacy, and in cancer survivors with higher personal control, and higher health literacy.
BACKGROUND: Oncokompas is a web-based self-management application that supports cancer survivors to monitor their health-related quality of life (HRQOL) and symptoms, and to obtain personalised feedback and tailored options for supportive care. In a large randomised controlled trial among survivors of head and neck cancer, colorectal cancer, and breast cancer and (non-)Hodgkin lymphoma, Oncokompas proved to improve HRQOL, and to reduce several tumour-specific symptoms. Effect sizes were however small, and no effect was observed on the primary outcome patient activation. Therefore, this study aims to explore which subgroups of cancer survivors may especially benefit from Oncokompas. MATERIALS AND METHODS: Cancer survivors (n = 625) were randomly assigned to the intervention group (access to Oncokompas, n = 320) or control group (6 months waiting list, n = 305). Outcome measures were HRQOL, tumour-specific symptoms, and patient activation. Potential moderators included socio-demographic (sex, age, marital status, education, employment), clinical (tumour type, stage, time since diagnosis, treatment modality, comorbidities), and personal factors (self-efficacy, personal control, health literacy, Internet use), and patient activation, mental adjustment to cancer, HRQOL, symptoms, and need for supportive care, measured at baseline. Linear mixed models were performed to investigate potential moderators. RESULTS: The intervention effect on HRQOL was the largest among cancer survivors with low to moderate self-efficacy, and among those with high personal control and those with high health literacy scores. Cancer survivors with higher baseline symptom scores benefitted more on head and neck (pain in the mouth, social eating, swallowing, coughing, trismus), and colorectal cancer (weight) specific symptoms. DISCUSSION: Oncokompas seems most effective in reducing symptoms in head and neck cancer and colorectal cancer survivors who report a higher burden of tumour-specific symptoms. Oncokompas seems most effective in improving HRQOL in cancer survivors with lower self-efficacy, and in cancer survivors with higher personal control, and higher health literacy.
Entities:
Keywords:
Supportive care; cancer survivorship; eHealth; health-related quality of life; moderators; self-management
Authors: Liza van Deursen; Anke Versluis; Rosalie van der Vaart; Lucille Standaar; Jeroen Struijs; Niels Chavannes; Jiska J Aardoom Journal: JMIR Cancer Date: 2022-06-14
Authors: Anouk S Schuit; Valesca van Zwieten; Karen Holtmaat; Pim Cuijpers; Simone E J Eerenstein; C René Leemans; Marije R Vergeer; Jens Voortman; Hakki Karagozoglu; Stijn van Weert; Mira Korte; Ruud Frambach; Margot Fleuren; Jan-Jaap Hendrickx; Irma M Verdonck-de Leeuw Journal: Eur J Cancer Care (Engl) Date: 2021-08-02 Impact factor: 2.328